Sumitomo Mitsui Trust Group Inc. Cuts Stake in CVS Health Corporation $CVS
by Tristan Rich · The Markets DailySumitomo Mitsui Trust Group Inc. lessened its holdings in shares of CVS Health Corporation (NYSE:CVS – Free Report) by 3.1% in the 4th quarter, Holdings Channel reports. The fund owned 2,868,224 shares of the pharmacy operator’s stock after selling 91,148 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in CVS Health were worth $227,622,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of CVS. Wellington Management Group LLP grew its stake in CVS Health by 391.6% during the 3rd quarter. Wellington Management Group LLP now owns 6,330,717 shares of the pharmacy operator’s stock valued at $477,273,000 after acquiring an additional 5,042,816 shares in the last quarter. Amundi grew its stake in CVS Health by 95.3% during the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock valued at $572,665,000 after acquiring an additional 3,637,943 shares in the last quarter. Capital Research Global Investors grew its stake in CVS Health by 24.5% during the 3rd quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock valued at $864,667,000 after acquiring an additional 2,253,531 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in CVS Health by 70.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 5,294,134 shares of the pharmacy operator’s stock valued at $399,125,000 after acquiring an additional 2,188,307 shares in the last quarter. Finally, Hamlin Capital Management LLC purchased a new stake in CVS Health during the 4th quarter valued at about $160,844,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.
CVS Health Stock Performance
CVS Health stock opened at $79.29 on Monday. The firm has a 50 day simple moving average of $75.92 and a 200-day simple moving average of $77.81. CVS Health Corporation has a 1-year low of $58.35 and a 1-year high of $85.15. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.84 and a quick ratio of 0.63. The stock has a market cap of $101.61 billion, a price-to-earnings ratio of 57.45, a price-to-earnings-growth ratio of 0.83 and a beta of 0.51.
CVS Health (NYSE:CVS – Get Free Report) last posted its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The business had revenue of $105.69 billion during the quarter, compared to analysts’ expectations of $103.67 billion. During the same quarter in the prior year, the company posted $1.19 EPS. The business’s revenue for the quarter was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, analysts expect that CVS Health Corporation will post 5.89 EPS for the current year.
CVS Health Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd will be issued a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 3.4%. The ex-dividend date is Thursday, April 23rd. CVS Health’s dividend payout ratio is currently 192.75%.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on CVS shares. Wolfe Research dropped their price objective on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a research note on Monday, March 2nd. Piper Sandler dropped their price objective on shares of CVS Health from $101.00 to $99.00 and set an “overweight” rating for the company in a research note on Tuesday, March 31st. Leerink Partners reissued an “outperform” rating and issued a $98.00 price target on shares of CVS Health in a research note on Thursday, March 5th. Bank of America dropped their price target on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research note on Tuesday, January 27th. Finally, The Goldman Sachs Group increased their price target on shares of CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. Twenty investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $94.95.
Read Our Latest Stock Analysis on CVS
About CVS Health
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
Featured Stories
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).